{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:59:12Z","timestamp":1791475152384,"version":"4.3.4"},"reference-count":74,"publisher":"American Chemical Society (ACS)","issue":"19","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["EB024495"],"award-info":[{"award-number":["EB024495"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Precision Molecular, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast activation protein (FAP) is a validated PET imaging target for the tumor microenvironment. Currently, most 18F-labeled FAP PET agents use Al\u2212F chemistry, with Al18F-FAPI-74 leading clinically, whereas C\u221218F tracers perform less effectively. Here, we developed (4-quinolinoyl)glycyl-2-cyanopyrrolidine (QCP)-based inhibitors incorporating a 6-fluoronicotinamide prosthetic group for stable C\u221218F labeling. Chelator incorporation improved hydrophilicity and enabled structurally matched radiometal- and 18F-labeled analogs from a common scaffold. The compounds exhibited high FAP inhibitory capacity (Ki = 9.9\u221256.7 pM) and favorable physicochemical properties (Log P7.4 = \u22123.1 \u00b1 0.1). The lead tracer, [18F]FPyQCP, was prepared by a one-pot, two-step radiosynthesis in 50\u221280% yields, with &amp;gt;99% radiochemical purity and molar activity of 74\u2212200 GBq\/\u03bcmol. In U87 xenografts, [18F]FPyQCP achieved high tumor uptake (23.3 \u00b1 2.1 %ID\/g) and favorable tumor-to-blood ratios (12.0 \u00b1 0.3) at 2 h. This modular labeling strategy establishes a versatile platform for next-generation FAP PET tracers and beyond.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01795","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:02:22Z","timestamp":1790359342000},"page":"22713-22736","source":"Crossref","is-referenced-by-count":0,"title":["[18F]FPyQCP: A Robust FAP-Targeted PET Tracer Integrating Covalent C\u221218F Labeling and Radiometal Chelation for Enhanced In Vivo Performance"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-7385","authenticated-orcid":true,"given":"Sangeeta Ray","family":"Banerjee","sequence":"first","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]},{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Boinapally","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-662X","authenticated-orcid":true,"given":"Il","family":"Minn","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-0367","authenticated-orcid":true,"given":"Deepankar","family":"Das","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-9474","authenticated-orcid":true,"given":"Laurence","family":"Carroll","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand K.","family":"Thotakura","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2262-7405","authenticated-orcid":true,"given":"Hyojin","family":"Cha","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Lisok","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Singh","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Alati","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Nam","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Du","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2290-488X","authenticated-orcid":true,"given":"Andrew G.","family":"Horti","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-3010","authenticated-orcid":true,"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Institutions , , , ,","place":["Baltimore, Maryland, United States, 21287"]},{"name":"UT Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"18","key":"2026100811124895200_cit1","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell Surface Glycoprotein of Reactive Stromal Fibroblasts as A Potential Antibody Target in Human Epithelial Cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"2026100811124895200_cit2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.mct-11-0340","article-title":"Rationale Behind Targeting Fibroblast Activation Protein\u2212Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy","volume":"11","author":"Brennen","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"2026100811124895200_cit3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The Biology And Function of Fibroblasts In Cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"2026100811124895200_cit4","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.xcrm.2025.102395","article-title":"Insights Into The Relevance of Targeting Fibroblasts to Control Cancer","volume":"6","author":"Boeker","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"51","key":"2026100811124895200_cit5","doi-asserted-by":"publisher","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","article-title":"Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts","volume":"274","author":"Park","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"6","key":"2026100811124895200_cit6","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/hep.510290631","article-title":"Fibroblast Activation Protein: A Cell Surface Dipeptidyl Peptidase and Gelatinase Expressed by Stellate Cells At the Tissue Remodelling Interface in Human Cirrhosis","volume":"29","author":"Levy","year":"1999","journal-title":"Hepatol"},{"issue":"20","key":"2026100811124895200_cit7","doi-asserted-by":"publisher","first-page":"19441","DOI":"10.1074\/jbc.C500092200","article-title":"Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein \u03b1","volume":"280","author":"Aertgeerts","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"11","key":"2026100811124895200_cit8","doi-asserted-by":"publisher","first-page":"7437","DOI":"10.1074\/jbc.M511112200","article-title":"Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity","volume":"281","author":"Edosada","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"15","key":"2026100811124895200_cit9","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1021\/bi062227y","article-title":"Ala657 and Conserved Active Site Residues Promote Fibroblast Activation Protein Endopeptidase Activity via Distinct Mechanisms of Transition State Stabilization","volume":"46","author":"Meadows","year":"2007","journal-title":"Biochem."},{"issue":"2","key":"2026100811124895200_cit10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.abb.2006.11.006","article-title":"Effect of fibroblast activation protein and \u03b12-antiplasmin cleaving enzyme on collagen Types I, III, and IV","volume":"457","author":"Christiansen","year":"2007","journal-title":"Archives Biochem, Biophys."},{"issue":"12","key":"2026100811124895200_cit11","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.1074\/jbc.272.12.7595","article-title":"Identification of the 170-kDa Melanoma Membrane-bound Gelatinase (Seprase) as a Serine Integral Membrane Protease","volume":"272","author":"Pin\u0303eiro-Sa\u0301nchez","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"3","key":"2026100811124895200_cit12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1021\/bi701921b","article-title":"Fibroblast Activation Protein Peptide Substrates Identified from Human Collagen I Derived Gelatin Cleavage Sites","volume":"47","author":"Aggarwal","year":"2008","journal-title":"Biochem."},{"issue":"11","key":"2026100811124895200_cit13","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.biocel.2004.05.006","article-title":"Purification, identification and characterisation of seprase from bovine serum","volume":"36","author":"Collins","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"4","key":"2026100811124895200_cit14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1182\/blood-2005-08-3452","article-title":"Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein","volume":"107","author":"Lee","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2026100811124895200_cit15","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2967\/jnumed.124.267923","article-title":"1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?","volume":"65","author":"Haberkorn","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026100811124895200_cit16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The Tumour Microenvironment in Pancreatic Cancer \ue5f8 Clinical Challenges and Opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"2026100811124895200_cit17","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","article-title":"Molecular Cloning of Fibroblast Activation Protein Alpha, A Member of The Serine Protease Family Selectively Expressed in Stromal Fibroblasts of Epithelial Cancers","volume":"91","author":"Scanlan","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"2026100811124895200_cit18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07241.x","article-title":"Fibroblast Activation Protein \u0391 Identifies Mesenchymal Stromal Cells From Human Bone Marrow","volume":"142","author":"Bae","year":"2008","journal-title":"Brit. J. Haemat."},{"issue":"6005","key":"2026100811124895200_cit19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein\u2212\u03b1","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"issue":"5","key":"2026100811124895200_cit20","first-page":"1639","article-title":"A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"2026100811124895200_cit21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000069863","article-title":"Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer","volume":"26","author":"Hofheinz","year":"2003","journal-title":"Onkologie"},{"issue":"11","key":"2026100811124895200_cit22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","article-title":"Phase II Trial Of Single Agent Val-Boropro (Talabostat) Inhibiting Fibroblast Activation Protein in Patients with Metastatic Colorectal Cancer","volume":"6","author":"Narra","year":"2007","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"2026100811124895200_cit23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective Inhibitors of Fibroblast Activation Protein (FAP) with A (4-Quinolinoyl)-Glycyl-2-Cyanopyrrolidine Scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"2026100811124895200_cit24","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure\u2212activity relationship and pharmacokinetic investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of Fibroblast Activation Protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026100811124895200_cit25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Inds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026100811124895200_cit26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","article-title":"The role of 68Ga-FAPI PET\/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience","volume":"61","author":"Koerber","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"7","key":"2026100811124895200_cit27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of 68Ga-Fapi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study","volume":"63","author":"Mona","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026100811124895200_cit28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1148\/radiol.2021204677","article-title":"Simultaneous FAPI PET\/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer","volume":"302","author":"Backhaus","year":"2022","journal-title":"Radiology"},{"issue":"6","key":"2026100811124895200_cit29","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2967\/jnumed.123.267281","article-title":"68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG","volume":"65","author":"Kline","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"13","key":"2026100811124895200_cit30","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1007\/s00259-020-04961-1","article-title":"The Battle on Time, Money and Precision: Da[18F] id vs. [68Ga]liath","volume":"47","author":"Sahnoun","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026100811124895200_cit31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41181-021-00144-x","article-title":"18F-labeled Tracers Targeting Fibroblast Activation Protein","volume":"6","author":"Lindner","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"9","key":"2026100811124895200_cit32","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","article-title":"[153Sm]Samarium-labeled FAPI-46 Radioligand Therapy In A Patient With Lung Metastases of a Sarcoma","volume":"48","author":"Kratochwil","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026100811124895200_cit33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026100811124895200_cit34","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1021\/acs.jmedchem.4c03133","article-title":"Modification of Asp\u2212Peptide Adapters: Giving the FAP-Targeted Radioligand a Squirrel Tail","volume":"68","author":"Meng","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026100811124895200_cit35","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1021\/acs.jmedchem.5c02795","article-title":"Exploring Covalent C\u221218F Bonding Strategies in the Design of FAP-Targeted Radiotracers","volume":"69","author":"Gao","year":"2026","journal-title":"J. Med. Chem."},{"key":"2026100811124895200_cit36","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1007\/s00259-021-05470-5","article-title":"Clinical Translational Evaluation of Al18F-NOTA-FAPI for fibroblast Activation Protein-Targeted Tumour Imaging","volume":"48","author":"Wang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026100811124895200_cit37","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","article-title":"Preclinical Evaluation And Pilot Clinical Study Of [18F]Alf-Labeled FAPI-Tracer For PET Imaging of Cancer-Associated Fibroblasts","volume":"12","author":"Hu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"2026100811124895200_cit38","doi-asserted-by":"publisher","first-page":"106878","DOI":"10.1016\/j.bioorg.2023.106878","article-title":"Preclinical Evaluation and Pilot Clinical PET Imaging Study of an 18F-labeled tracer targeting fibroblast activation protein","volume":"141","author":"Fu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"2026100811124895200_cit39","doi-asserted-by":"publisher","first-page":"115993","DOI":"10.1016\/j.ejmech.2023.115993","article-title":"Synthesis And Preclinical Evaluation of Novel 18F-Labeled Fibroblast Activation Protein Tracers For Positron Emission Tomography Imaging of Cancer-Associated Fibroblasts","volume":"264","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"2026100811124895200_cit40","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1021\/acs.molpharmaceut.4c01360","article-title":"Preclinical and First-In-Human Imaging of Novel [18F]F-FAPI-FUSCC-07 Tracer: Comparative Prospective Study with [18F]F-FAPI-42 and [18F]F-FAPI-74","volume":"22","author":"Bian","year":"2025","journal-title":"Mol. Pharm."},{"issue":"12","key":"2026100811124895200_cit41","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.2967\/jnumed.120.242958","article-title":"Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor","volume":"61","author":"Toms","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"11","key":"2026100811124895200_cit42","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1021\/acsptsci.3c00187","article-title":"Design, Synthesis, and Evaluation of 18F-Labeled Tracers Targeting Fibroblast Activation Protein for Brain Imaging","volume":"6","author":"Yu","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2026100811124895200_cit43","doi-asserted-by":"publisher","first-page":"115862","DOI":"10.1016\/j.ejmech.2023.115862","article-title":"Next generation fibroblast activation protein (FAP) targeting PET tracers - The tetrazine ligation allows an easy and convenient way to 18F-labeled (4-quinolinoyl)glycyl-2-cyanopyrrolidines","volume":"262","author":"Poulie","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"2026100811124895200_cit44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ph17070833","article-title":"Automated Radiosynthesis of [18F]FluoFAPI and Its Dosimetry and Single Acute Dose Toxicological Evaluation","volume":"17","author":"Witek","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"9","key":"2026100811124895200_cit45","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1021\/acs.jmedchem.3c02402","article-title":"Druglike, 18F-labeled PET Tracers Targeting Fibroblast Activation Protein","volume":"67","author":"Tanc","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026100811124895200_cit46","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1021\/acs.bioconjchem.5c00366","article-title":"Synthesis and Preclinical Evaluation of Druglike 18F-Labeled Fibroblast Activation Protein (FAP) Inhibitors with Enhanced Tumor Retention","volume":"36","author":"Adhikari","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"2026100811124895200_cit47","doi-asserted-by":"publisher","first-page":"117513","DOI":"10.1016\/j.ejmech.2025.117513","article-title":"Synthesis of piperazine-based fluorinated fibroblast activation protein inhibitors for the development of a novel 18F-labeled PET imaging probe","volume":"290","author":"Ko\u0308chel","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"2026100811124895200_cit48","doi-asserted-by":"publisher","first-page":"16331","DOI":"10.1021\/acs.jmedchem.5c01228","article-title":"Novel [18F]Fluorine-Based PET Tracers with Polar But Nonbasic Linkers to Image the Fibroblast Activation Protein in the Microenvironment of Tumors","volume":"68","author":"Ko\u0308chel","year":"2025","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026100811124895200_cit49","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.3390\/pharmaceutics15122749","article-title":"Preparation of 18F-Labeled Tracers Targeting Fibroblast Activation Protein via Sulfur [18F]Fluoride Exchange Reaction","volume":"15","author":"Craig","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"2026100811124895200_cit50","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00259-023-06169-5","article-title":"A Radiohybrid Theranostics Ligand Labeled with Fluorine-18 and Lutetium-177 for Fibroblast Activation Protein-Targeted Imaging And Radionuclide Therapy","volume":"50","author":"Yang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026100811124895200_cit51","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1039\/D4MD00591K","article-title":"Enhancing The Radionuclide Theranostic Concept Through the Radiohybrid Approach","volume":"16","author":"Kro\u0308nke","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"5","key":"2026100811124895200_cit52","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors","volume":"61","author":"Wurzer","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"7","key":"2026100811124895200_cit53","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1021\/acs.jmedchem.0c02171","article-title":"Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules","volume":"64","author":"Slania","year":"2021","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026100811124895200_cit54","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1007\/s00259-022-05933-3","article-title":"Hetero-bivalent agents targeting FAP and PSMA","volume":"49","author":"Boinapally","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026100811124895200_cit55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","article-title":"Quantitation of Fibroblast Activation Protein (FAP)-Specific Protease Activity in Mouse, Baboon and Human Fluids And Organs","volume":"4","author":"Keane","year":"2014","journal-title":"FEBS Open Bio"},{"issue":"4","key":"2026100811124895200_cit56","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00259-024-06969-3","article-title":"Effect of Molar Dose on the in Vivo Tissue Biodistribution Profile of FAP-Targeted Radioligand Therapeutics","volume":"52","author":"Galbiati","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"2026100811124895200_cit57","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1007\/s00259-025-07141-1","article-title":"Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study","volume":"52","author":"Bilinska","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"2026100811124895200_cit58","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1007\/s00259-025-07071-y","article-title":"The Molar Dose of FAPI Administered Impacts on the FAP-Targeted PET Imaging And Therapy in Mouse Syngeneic Tumor Models","volume":"52","author":"Liu","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026100811124895200_cit59","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2967\/jnumed.121.262098","article-title":"An Improved 211At-Labeled Agent for PSMA-Targeted \u03b1-Therapy","volume":"63","author":"Mease","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026100811124895200_cit60","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3390\/molecules25102314","article-title":"Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals","volume":"25","author":"Evans","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"2026100811124895200_cit61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2967\/jnumed.120.257402","article-title":"(11)C Dosimetry Scans Should Be Abandoned","volume":"62","author":"Zanotti-Fregonara","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026100811124895200_cit62","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1073\/pnas.1812155116","article-title":"PET Imaging Of Microglia By Targeting Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R)","volume":"116","author":"Horti","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"2026100811124895200_cit63","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"2026100811124895200_cit64","doi-asserted-by":"publisher","first-page":"113678","DOI":"10.1016\/j.jconrel.2025.113678","article-title":"FAP-targeted delivery of radioiodinated probes: A Progressive Albumin-Driven Strategy for Tumor Theranostics","volume":"382","author":"Li","year":"2025","journal-title":"J. Control. Release"},{"issue":"12","key":"2026100811124895200_cit65","doi-asserted-by":"publisher","first-page":"12940","DOI":"10.1021\/acs.jmedchem.5c00837","article-title":"Design, Structure Optimization, and Preclinical Evaluation of 188Re-Labeled FAPI for Targeted Radionuclide Therapy","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026100811124895200_cit66","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/(SICI)1521-3765(19990702)5:7&lt;1974::AID-CHEM1974&gt;3.0.CO;2-X","article-title":"Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy","volume":"5","author":"Heppeler","year":"1999","journal-title":"Chem.\ue5f8Eur. J."},{"issue":"18","key":"2026100811124895200_cit67","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1016\/j.poly.2006.06.039","article-title":"Structure and Thermal Analysis of the Gallium Complex of 1,4,7,10-Tetraazacyclo-Dodecane-N,N\u2032,N\u2033,N\u2034-Tetraacetic Acid (DOTA)","volume":"25","author":"Viola","year":"2006","journal-title":"Polyhedron"},{"issue":"3","key":"2026100811124895200_cit68","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity Profiles for Human Somatostatin Receptor Subtypes SST1\u2212SST5 of Somatostatin Radiotracers Selected for Scintigraphic and Radiotherapeutic Use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"issue":"9","key":"2026100811124895200_cit69","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","article-title":"Unexpected Sensitivity of SST2 Antagonists to N-Terminal Radiometal Modifications","volume":"53","author":"Fani","year":"2012","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026100811124895200_cit70","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of Fibroblast Activation Protein in Health and Malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Met. Rev."},{"issue":"4","key":"2026100811124895200_cit71","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1021\/jm9015813","article-title":"One Step Radiosynthesis of 6-[18F]Fluoronicotinic Acid 2,3,5,6-Tetrafluorophenyl Ester ([18F]F-Py-TFP): A New Prosthetic Group for Efficient Labeling of Biomolecules with Fluorine-18","volume":"53","author":"Olberg","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026100811124895200_cit72","unstructured":"Ray, S. B.; Boinapally, S. P.; Pomper, M. G.; Horti, A.; Das, D.; Minn, I.; Cha, H.; Laurence, C.\n          Heterobivalent and Homobivalent Agents Targeting Fibroblast Activation Protein Alpha and\/or Prostate-Specific Membrane Antigen. U.S. Patent 21 November. 20240382629 A1, 2024."},{"issue":"6","key":"2026100811124895200_cit73","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/acs.bioconjchem.5b00679","article-title":"Preclinical Comparative Study of 68Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA","volume":"27","author":"Ray Banerjee","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"2026100811124895200_cit74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0005-2744(69)90420-3","article-title":"Kinetics of The Reversible Inhibition of Enzyme-Catalysed Reactions By Tight-Binding Inhibitors","volume":"185","author":"Morrison","year":"1969","journal-title":"Biochim. Biophys. Acta Enzymol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01795","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22713\/68662002\/jm6c01795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22713\/68662002\/jm6c01795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:34:42Z","timestamp":1791473682000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/19\/22713\/5439060\/18F-FPyQCP-A-Robust-FAP-Targeted-PET-Tracer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":74,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01795","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}